GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeartSciences Inc (NAS:HSCS) » Definitions » Cash Conversion Cycle

HSCS (HeartSciences) Cash Conversion Cycle : 0.00 (As of Jan. 2025)


View and export this data going back to 2022. Start your Free Trial

What is HeartSciences Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

HeartSciences's Days Sales Outstanding for the three months ended in Jan. 2025 was 0.
HeartSciences's Days Inventory for the three months ended in Jan. 2025 was 0.
HeartSciences's Days Payable for the three months ended in Jan. 2025 was 0.
Therefore, HeartSciences's Cash Conversion Cycle (CCC) for the three months ended in Jan. 2025 was 0.00.


HeartSciences Cash Conversion Cycle Historical Data

The historical data trend for HeartSciences's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartSciences Cash Conversion Cycle Chart

HeartSciences Annual Data
Trend Apr20 Apr21 Apr22 Apr23 Apr24
Cash Conversion Cycle
3,951.52 15,147.50 9,040.26 1,606.00 6,874.17

HeartSciences Quarterly Data
Apr20 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,383.96 - - - -

Competitive Comparison of HeartSciences's Cash Conversion Cycle

For the Medical Devices subindustry, HeartSciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeartSciences's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeartSciences's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where HeartSciences's Cash Conversion Cycle falls into.


;
;

HeartSciences Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

HeartSciences's Cash Conversion Cycle for the fiscal year that ended in Apr. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+39693.75-32819.58
=6,874.17

HeartSciences's Cash Conversion Cycle for the quarter that ended in Jan. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeartSciences  (NAS:HSCS) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


HeartSciences Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of HeartSciences's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


HeartSciences Business Description

Traded in Other Exchanges
N/A
Address
550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
Executives
David R. Wells director 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent director 750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz director, officer: See Remarks 3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson director, officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092